brand logo

Am Fam Physician. 2006;73(8):1446

Clinical Question: Are conventional anti-psychotic agents safer than atypical agents in older patients?

Setting: Population-based

Study Design: Cohort (retrospective)

Synopsis: A recent public health advisory ( warned that there is a twofold increase in the risk of death among older patients with dementia when given atypical antipsychotic agents such as aripiprazole (Abilify), clozapine (Clozaril), olanzapine (Zyprexa), quetiapine (Seroquel), risperidone (Risperdal), and ziprasidone (Geodon). Researchers performed this federally sponsored study to determine whether conventional agents (e.g., haloperidol [Haldol], thiothixene [Navane], loxapine [Loxitane]) carry a similar risk.

They identified patients older than 65 years who had filled a first prescription for any antipsychotic agent between 1994 and 2003. Mortality data came from the Medicare Death Master File, and they used administrative data sets to establish comorbidities, hospitalizations, nursing home residence, and use of other medications. They identified 9,142 patients using a conventional antipsychotic and 13,748 using an atypical agent. Patients taking conventional antipsychotics were more likely to have heart disease or cancer, but they were less likely to have other mood disorders or take other psychotropic medications. In the unadjusted analysis there were more deaths among users of conventional agents (17.9 versus 14.6 percent; P < .001; number needed to harm = 30; 95% confidence interval [CI], 23 to 43). This corresponds to an unadjusted hazard ratio of 1.51 (95% CI, 1.43 to 1.59). After adjusting for comorbidities, the relative risk was somewhat lower but still statistically significant (1.37; 95% CI, 1.27 to 1.49). The risk was greatest in the first 40 days after beginning therapy, in patients without dementia, and in patients taking a higher-than-median dose of the conventional antipsychotic medication.

Bottom Line: It seems reasonable to conclude that conventional and atypical antipsychotic agents are associated with an increased risk of death in older patients. The limitations of this study do not allow for a definite conclusion that older agents are less safe than newer agents. (Level of Evidence: 2b)

POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, see Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see

To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to

This series is coordinated by Natasha Pyzocha, DO, contributing editor.

A collection of POEMs published in AFP is available at

Continue Reading

More in AFP

Copyright © 2006 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.